96847-55-1

Usage

Uses

Used in Pharmaceutical Industry:
Levomilnacipran is used as an antidepressant medication for the treatment of major depressive disorder. It is employed to alleviate symptoms associated with depression by modulating the levels of serotonin and norepinephrine, neurotransmitters that play a key role in mood and emotional regulation. The medication is available in extended-release formulations, allowing for once-daily dosing, which can improve patient compliance and therapeutic outcomes. However, due to its potential side effects and drug interactions, it is essential to consult with a healthcare professional before its use.

Upstream product

• 140-29-4 phenylacetonitrile 
• 86181-08-0 cis-(±)-1-phenyl-2-(aminomethyl)-N,N-diethylcyclopropanecarboxamide hydrochloride 
• 50583-51-2 O,O′-di-p-anisoyl-D-tartaric acid 
• 105310-09-6 milnacipran 
• 1374648-84-6 (1R,2S)-cis-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide (L)-(+)-mandelate 
• 98-80-6 phenylboronic acid 
• 692730-97-5 (Z)-4-(tert-butyldimethylsiloxy)-3-phenylbut-2-en-1-ol 
• 32634-66-5 Di-p-toluoyl-L-tartaric acid 
• 1237261-65-2 (1S,2R)-2-((1,3-dioxoisoindolin-2-yl)methyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide-cyclopropanecarboxamide 
• 1374648-80-2 (1S,2R)-cis-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide (D)-(-)-mandelate 

Downstream Products

• 1418000-39-1 N,N-diethyl-2-methyl-1-phenylcycloprop-2-enecarboxamide 
• 105310-06-3 2-(aminomethyl)-1-phenylcyclopropanecarboxamide 

Relevant academic research and scientific papers

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Preparation of leveminacipran hydrochloride

The invention discloses a novel preparation method for synthesizing leveminacipran hydrochloride, and relates to a compound represented by a formula A. According to the invention, each step of reaction is simple in operation and mild in condition, use of

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Preparation method of levomilnacipran hydrochloride

The invention provides a preparation method of levomilnacipran hydrochloride. According to the preparation method, a mixed liquid is obtained through a mixed reaction of a compound adopting the structure shown in the formula (II) and alkali; then acid is

PROCESS FOR PREPARING LEVOMILNACIPRAN

The present invention refers to a new process for preparing levomilnacipran, in particular to a process for the resolution of racemic tw-milnacipran with a derivative of optically active phenylglycine.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.

Milnacipran as a challenging example of aminomethyl substrate for lipase-catalyzed kinetic resolution

A biocatalysed procedure for the kinetic resolution of milnacipran, (±)-1 was developed and optimized by careful choice of the reaction parameters. The reaction of (±)-1 with methyl iso-butyrate as acyl donor in the presence of Novozyme 435 in tert-butyl

AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS

The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers of formula (I) or its pharmaceutically acceptable salt thereof wherein R1 and R2 are represents independently selected from the group consisting of hydrogen, lower alkyl, lower aryl, and lower-alkylaryl, which aryl or alkylaryl group is optionally substituted by a halogen atom.

PROCESS FOR PREPARING LEVOMILNACIPRAN HCL

The invention relates to one-pot process for preparing (1S,2R)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcyclopropane of formula (I) comprising the step of reacting (1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropanecarboxamide successively with the following reactants 1) triethyl orthoformate and methanesulfonic acid or triethylamine and methanesulfonyl chloride, 2) a phthalimidating agent, 3) aqueous EtNH2, wherein the reaction is carried out in toluene. In another aspect the invention concerns a process for preparing (1S,2R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropanecarboxamide trough a step of crystallization of (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one.

Synthesis and characterization of process related impurities of (±)-Milnacipran

Milnacipran is a cyclopropane derivative, used as an anti depressant drug. During the process development of milnacipran, four process related potential impurities were detected in high performance liquid chromatography. All these impurities were identified, synthesized and subsequently characterized by their respective spectral data (IR, LC-MS, 1HNMR, and 13C NMR) as described in this article.